Effect of exogenous hydrogen sulfide on bone metabolism in an ovariectomized osteoporotic rat model

doi:10.12307/2021.161

Abstract

Abstract: BACKGROUND: Exogenous hydrogen sulfide has an important effect on the formation and differentiation of osteoblasts, which are important functional cells in the development of osteoporotic disease. The effect of exogenous hydrogen sulfide on osteoporosis levels and related hormones has not been studied.
OBJECTIVE: To investigate the correlation between endogenous hydrogen sulfide concentration and osteoporosis, and the effect of exogenous hydrogen sulfide supplementation on the biochemical and hormonal parameters commonly used in the clinical follow-up of bone metabolism.
METHODS: Sixty rats were randomly divided into sham-operated group, model group, and exogenous hydrogen sulfide group (n=20 per group). A classical osteoporosis model was established by removing both ovaries of rats in the latter two groups. No ovariectomy was conducted in the sham-operated group. Rats in the sham-operated and model groups were intraperitoneally given 1 mg/kg normal saline, while those in the exogenous hydrogen sulfide group intraperitoneally injected 100 μg/kg GYY4137, a slow-released agent of exogenous hydrogen sulfide. Treatments in each group were conducted twice a day, for 12 weeks. Plasma hydrogen sulfide concentration, blood calcium and phosphorus concentrations, alkaline phosphatase activity, osteocalcin, calcitonin, parathyroid hormone, and leptin laboratory index data of each group were analyzed by quantitative comparison.
RESULTS AND CONCLUSION: Bone mineral density of the L5, plasma hydrogen sulfide, calcium, phosphorus, alkaline phosphatase, calcitonin concentrations were significantly lower, and osteocalcin, parathyroid hormone, and leptin levels were significantly higher in the model group compared with the sham-operated group at weeks 8 and 12 (P < 0.05). There were no significant differences between the sham-operated and exogenous hydrogen sulfide groups at weeks 8 and 12 in terms of L5 bone mineral density, plasma hydrogen sulfide, phosphorus, osteocalcin, calcitonin, parathyroid hormone and leptin levels (P > 0.05). Whereas blood calcium concentration and alkaline phosphatase activity were still decreased in the exogenous hydrogen sulfide group compared with the sham-operated group (P < 0.05). Compared with the model group, plasma hydrogen sulfide, blood calcium and phosphorus concentrations were elevated and leptin level was decreased in the exogenous hydrogen sulfide group (P < 0.05), while the differences in L5 bone mineral density, alkaline phosphatase activity, osteocalcin, calcitonin and parathyroid hormone levels at weeks 8 and 12 were not significant between the two groups (P > 0.05). Therefore, in the ovariectomized osteoporotic rat model, endogenous hydrogen sulfide concentration was negatively correlated with the severity of osteoporosis, and exogenous supplementation to increase plasma hydrogen sulfide concentration could improve or reverse plasma calcium, phosphorus and some hormone indexes related to bone metabolism. To conclude, plasma hydrogen sulfide concentration and osteoporosis are correlated, and exogenous hydrogen sulfide supplementation has a potential therapeutic effect on osteoporosis which is caused by estrogen reduction.

Key words: estrogen, osteoporosis, hydrogen sulfide, bone metabolism, calcium, phosphorus, hormone

CLC Number:

Lai Honghui, Liu Yue, Li Tiyuan, Pan Xiaohua, Xu Zhongshi. Effect of exogenous hydrogen sulfide on bone metabolism in an ovariectomized osteoporotic rat model[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(29): 4632-4637.

Figures/Tables 6

References

[1] FORCIEA MA , MCLEAN RM , QASEEM A. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Int Med. 2017;167(12):899.
[2] KANIS JA, COOPER C, RIZZOLI R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44.
[3] KALU DN. The ovariectomized model of postmenopausal bone loss. Bone Miner. 1991;15:175-191.
[4] MARCUS R, FELDMAN D, KELSEY J. Osteoporosis. Academic Press, 1996: 677-679.
[5] MUTHUSAMI S, RAMACHANDRAN I, MUTHUSAMY B, et al. Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. Clin Chim Acta. 2005;360:81-86.
[6] ALMEIDA M, HAN L, MARTIN-MILLAN M, et al. Skeletal involution by ageassociated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282(37):27285-27297.
[7] BASU S, MICHAËLSSON K, OLOFSSON H, et al. Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun. 2001;288:275-279.
[8] MAGGIO D, BARABANI M, PIERANDREI M, et al. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab. 2003;88:1523-1527.
[9] FINKEL T, HOLBROOK NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239-247.
[10] MANOLAGAS SC. From estrogen-centric to aging and oxidative stress:a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010;31(3):266-300.
[11] WEITZMANN MN, PACIFICI R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006;116(5):1186-1194.
[12] WHITEMAN M, ARMSTRONG JS, CHU SH, et al. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite ‘scavenger’? J Neurochem. 2004;90:765-768.
[13] KIMURA Y, GOTO Y, KIMURA H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal. 2010;12:1-13.
[14] ABE K, KIMURA H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16(3):1066-1071.
[15] WANG R. Two’s company, three’s a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J. 2002;16:1792-1798.
[16] XU ZS,WANG XY,XIAO DM, et al. Hydrogen sulfide protects MC3T3-E1 osteoblastic cells against H2O2-induced oxidative damage-implications for the treatment of osteoporosis. Free Radic Biol Med. 2011;50(10) : 1314-1323.
[17] LELOVAS PP, XANTHOS TT, THORMA SE, et al. The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008;58(5): 424-430.
[18] LIU XL, LI CL, LU WW, et al. Skeletal site-specific response to ovariectomy in a rat model: change in bone density and microarchitecture. Clin Oral Implants Res. 2015;26(4):392-398.
[19] JAIN S, CAMACHO P. Use of bone turnover markers in the management of osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2018;25(6): 366-372.
[20] SAHA MK, AGRAWAL P, SAHA SG, et al. Evaluation of Correlation between Salivary Calcium, Alkaline Phosphatase and Osteoporosis- A Prospective, Comparative and Observational Study. J Clin Diagn Res. 2017;11(3):ZC63-ZC66.
[21] BOYACIOGLU O, ORENAY-BOYACIOGLU S, YILDIRIM H, et al. Boron intake, osteocalcin polymorphism and serum level in postmenopausal osteoporosis. J Trace Elem Med Biol. 2018;48:52-56.
[22] LEDER, BZ. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy. Curr Osteoporos Rep. 2017; 15(2):110-119.
[23] CREPALDI G, ROMANATO G, TONIN P, et al. Osteoporosis and body composition. J Endocrinol Invest. 2007;30(6 Suppl):42.
[24] RACHNER TD, KHOSLA S, HOFBAUER LC. Osteoporosis:now and the future. Lancet. 2011;377(9773):1276-1287.
[25] KOMM BS, TERPENING CM, BENZ DJ, et al. Estrogen binding,receptor mRNA,and biologic response in osteoblast-like osteosarcoma cells. Science. 1988;241(4861):81-84.
[26] ERIKSEN EF, COLVARD DS, BERQ NJ, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988;241(4861):84-86.
[27] OURSLE MJ,OSDOBY P, PYFFEROEN J, et al. Alian osteoclast as estrogen target cells. Proc Natl Acad Sci. 1991;88(15):6613-6617.
[28] MANO H, YUASA T, KAMEDA T, et al. Mamnalian mature osteoclast as estrogen target cells. Biochem Biophys Res Commun. 1996;223(3): 637-642.
[29] ASSEY HM, FLANAGAN AM. Humano steoelasts derive from CD14-Positive monoeytes. Br J Haematol. 1999;106:167-170.
[30] ADAEHI JD, PAPAIOANNOU A. Cortieosteroid-Indueed osteoporsis: detdetion and management. Drug Saf. 2001;24(8):607-624.
[31] LUMACHI F, ERMANI M, CAMOZZI V, et al. Changes of bone formation markers osteocalcin and bone-specific alkaline phosphatase in postmenopausal women with osteoporosis. Ann N Y Acad Sci. 2009; 1173(1): 60-63.
[32] ALMEIDA M, HAN L, MARTIN-MILLAN M, et al. Skeletal involution by ageassociated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282(37):27285-27297.
[33] LV M, LIU Y, XIAO TH, et al. GYY4137 stimulates osteoblastic cell proliferation and differentiation via an ERK1/2-dependent anti-oxidant mechanism. Am J Transl Res. 2017;9(3):1183.
[34] GAMBARI L, LISIGNOLI G, CATTINI L, et al. Sodium hydrosulfide inhibits the differentiation of osteoclast progenitor cells via NRF2-dependent mechanism. Pharmacol Res. 2014;87:99-112.
[35] LI J, YUAN YQ, ZHANG L, et al. Exogenous hydrogen sulfide protects against high glucoseinduced apoptosis and oxidative stress by inhibiting the STAT3/HIF1α pathway in H9c2 cardiomyocytes. Exp Ther Med. 2019;18(5):3948-3958.
[36] ZHOU Q, ZHU L, ZHANG D, et al. Oxidative Stress-Related Biomarkers in Postmenopausal Osteoporosis: A Systematic Review and Meta-Analyses. Dis Markers. 2016;2016:7067984.
[37] HINE C, HARPUTLUGIL E, ZHANG Y, et al. Endogenous hydrogen sulfide production is essential for dietary restriction benefits. Cell. 2015; 160(1-2):132-144.